PVR and melanoma: Interestingly, while TIGIT+ NK cells demonstrated a higher lytic potential, they paradoxically exhibit lower actual lytic activity against CD155+ major histocompatibility complex (MHC)-class I deficient melanoma cells than their TIGIT- counterparts [34].